Miscellaneous

systematic review meta-analysis network meta-analysis

Select melanomasarcoma adjuvant settinguncoded clinical condition ***All type of patient       anti-CTLA-4anti-PD-1BRAF inhibitorcombined BRAF and MEK inhibitioninterferonwhole population Interferon alphatrametinib + dabrafenib vemurafenibipilimumabnivolumabpazopanibpembrolizumab vs placebo or control       adjuvant

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	relapse (12)progression or death (progression free survival PFS) (6)recurrence free survival (4)death (overall survival) (4)distant metastasis free survival (4)Grade 3–5 drug-related AEs (2)vitiligo any grade (1)vitiligo grade 3-4 (1)aaa (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	relapse	progression or death (progression free survival PFS)
melanoma
Interferon alpha
EORTC18991 (Eggermont), 2008	PEG IFN alpha-2b (I M)	observation	adjuvant			suggesting
EORTC18871/DKG 80-1 stage III	rIFN alpha-2b	observation				-
ipilimumab
EORTC 18071 (Eggermont), 2015        NCT	ipilimumab	placebo	adjuvant	adjuvant	Low risk of bias	conclusive
nivolumab
CheckMate 238 subgroup IIIB-C	nivolumab	ipilimumab				suggesting
pembrolizumab
KEYNOTE-054, 2018      NCT	pembrolizumab	placebo	adjuvant	adjuvant	Low risk of bias	conclusive
trametinib + dabrafenib
COMBI-AD, 2017      NCT	trametinib and dabrafenib	placebo	adjuvant		Low risk of bias	suggesting
vemurafenib
BRIM 8 (cohort IIIC)	vemurafenib	placebo				negative
sarcoma
pazopanib
PALETTE (van der Graaf), 2012      NCT	pazopanib	placebo				suggesting